scholarly journals The Role of Bridging Therapy in Hepatocellular Carcinoma

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Roberto Galuppo ◽  
Angie McCall ◽  
Roberto Gedaly
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Bridging Therapy ◽  
Primary Malignancy ◽  
Single Center Experience ◽  
Increased Risk ◽  
Control Tumor ◽  
End Stage

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for 7% of all cancers worldwide. Most cases of HCC develop within an established background of chronic liver disease. For that reason, liver resection is only possible in selected patients. Liver transplantation has become the treatment of choice in patients with HCC, end-stage liver disease, and significant portal hypertension. Shortage of organ donors has resulted in overall increase of waiting list time with increased risk of dropout due to tumor progression. Neoadjuvant therapies have emerged as an alternative to control tumor growth in patients while waiting. The aim of this study is to review the literature on the role of bridging therapy and downstaging prior to liver transplantation in patients with HCC. We are also presenting our single-center experience of 96 patients undergoing transplantation for HCC with and without bridging therapy.

scholarly journals Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases?

2020 ◽  
Vol 21 (15) ◽  
pp. 5242 ◽  
Author(s):  
Misaq Heydari ◽  
María Eugenia Cornide-Petronio ◽  
Mónica B. Jiménez-Castro ◽  
Carmen Peralta
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Therapeutic Target ◽  
Liver Diseases ◽  
Therapeutic Strategies ◽  
Potential Therapeutic Target ◽  
Surgical Interventions ◽  
Scientific Controversies

The review describes the role of adiponectin in liver diseases in the presence and absence of surgery reported in the literature in the last ten years. The most updated therapeutic strategies based on the regulation of adiponectin including pharmacological and surgical interventions and adiponectin knockout rodents, as well as some of the scientific controversies in this field, are described. Whether adiponectin could be a potential therapeutic target for the treatment of liver diseases and patients submitted to hepatic resection or liver transplantation are discussed. Furthermore, preclinical and clinical data on the mechanism of action of adiponectin in different liver diseases (nonalcoholic fatty disease, alcoholic liver disease, nonalcoholic steatohepatitis, liver cirrhosis and hepatocellular carcinoma) in the absence or presence of surgery are evaluated in order to establish potential targets that might be useful for the treatment of liver disease as well as in the practice of liver surgery associated with the hepatic resections of tumors and liver transplantation.

Liver transplantation for end-stage alcoholic liver disease: a single-center experience from mainland China

Alcohol ◽  
2010 ◽  
Vol 44 (3) ◽  
pp. 217-221 ◽  
Author(s):  
Gui-hua Chen ◽  
Yang Yang ◽  
Min-qiang Lu ◽  
Chang-jie Cai ◽  
Qi Zhang ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Alcoholic Liver Disease ◽  
Mainland China ◽  
Single Center ◽  
Single Center Experience ◽  
End Stage

Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease Era

2010 ◽  
Vol 210 (5) ◽  
pp. 727-734 ◽  
Author(s):  
David M. Levi ◽  
Andreas G. Tzakis ◽  
Paul Martin ◽  
Seigo Nishida ◽  
Eddie Island ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Liver Disease ◽  
End Stage Liver Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document